Persistent infection by specific oncogenic human papillomaviruses (HPVs) is established as the necessary cause of cervix cancer. DNA sequence differences between HPV genomes determine whether an HPV has the potential to cause cancer. Of the more than 100 HPV genotypes characterized at the genetic level, at least 15 are associated, to varying degrees, with cervical cancer. Classification based on nucleotide similarity places nearly all HPVs that infect the cervicovaginal area within the α-PV genus. Within this genus, phylogenetic trees inferred from the entire viral genome cluster all cancer-causing types together, suggesting the existence of a common ancestor for the oncogenic HPVs. However, in separate trees built from the early open reading frames (ORFs; i.e. E1, E2, E6, E7) or the late ORFs (i.e. L1, L2), the carcinogenic potential sorts with the early region of the genome, but not the late region. Thus, genetic differences within the early region specify the pathogenic potential of α-HPV infections. Since the HPV genomes are monophyletic and sites are highly correlated across the genome, diagnosis of oncogenic types and non-oncogenic types can be accomplished using any region across the genome. Here we review our current understanding of the evolutionary history of the oncogenic HPVs, in particular, we focus on the importance of viral genome heterogeneity and discuss the genetic basis for the oncogenic phenotype in some but not all α-PVs.

Keywords:
Human papillomavirus, Cervix cancer, Evolution, Phylogeny
1.
zur Hausen H: Human papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol 1977;78:1–30.
2.
Durst M, Gissmann L, Ikenberg H, zur Hausen H: A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 1983;80:3812–3815.
3.
Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H: A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. Embo J 1984;3:1151–1157.
4.
Gissmann L, Diehl V, Schultz CH, zur Hausen H: Molecular cloning and characterization of human papilloma virus DNA derived from a laryngeal papilloma. J Virol 1982;44:393–400.
5.
Parkin DM, Bray F: Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24 (suppl 3):S11–S25.
6.
Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.
7.
Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S: Human papillomavirus and cervical cancer. Lancet 2007;370:890–907.
8.
Van Ranst MA, Tachezy R, Delius H, Burk RD: Taxonomy of the human papillomaviruses. Papillomavirus Rep 1993;3:61–65.
9.
de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H: Classification of papillomaviruses. Virology 2004;324:17–27.
10.
Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD: The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005;337:76–84.
11.
Narechania A, Chen Z, Desalle R, Burk RD: Phylogenetic incongruence among oncogenic genital alpha human papillomaviruses. J Virol 2005;79:15503–15510.
12.
Castle PE, Rodriguez AC, Porras C, Herrero R, Schiffman M, Gonzalez P, Hildesheim A, Burk RD: A comparison of cervical and vaginal human papillomavirus. Sex Transm Dis 2007;34:849–855.
13.
Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518–527.
14.
Munoz N, Castellsague X, de Gonzalez AB, Gissmann L: Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24(suppl 3):S1–S10.
15.
Garcia-Vallve S, Alonso A, Bravo IG: Papillomaviruses: different genes have different histories. Trends Microbiol 2005;13:514–521.
16.
Bosch FX, de Sanjose S: The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 2007;23:213–227.
17.
IARC IAfRoC: Monographs on the Evolution of the Carcinogenic Risk to Humans: Human Papillomaviruses. Lyon, IARC Scientific Publications, 1995.
18.
Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621–632.
19.
Pirog EC, Kleter B, Olgac S, Bobkiewicz P, Lindeman J, Quint WG, Richart RM, Isacson C: Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol 2000;157:1055–1062.
20.
Altekruse SF, Lacey JV, Brinton LA, Gravitt PE, Silverberg SG, Barnes WA, Greenberg MD, Hadjimichael OC, McGowan L, Mortel R, Schwartz PE, Hildesheim A: Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinoma and squamous cell carcinoma: Northeastern united states. Am J Obstet Gynecol 2003;188:657–663.
21.
Castellsague X, Munoz N: Chapter 3: Cofactors in human papillomavirus carcinogenesis: role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst 2003;31:20–28.
22.
Narechania A, Terai M, Burk RD: Overlapping reading frames in closely related human papillomaviruses result in modular rates of selection within E2. J Gen Virol 2005;86:1307–1313.
23.
Deau MC, Favre M, Orth G: Genetic heterogeneity among human papillomaviruses (HPV) associated with epidermodysplasia verruciformis: evidence for multiple allelic forms of HPV 5 and HPV 8 E6 genes. Virology 1991;184:492–503.
24.
Calleja-Macias IE, Kalantari M, Allan B, Williamson AL, Chung LP, Collins RJ, Zuna RE, Dunn ST, Ortiz-Lopez R, Barrera-Saldana HA, Cubie HA, Cuschieri K, Villa LL, Bernard HU: Papillomavirus subtypes are natural and old taxa: phylogeny of human papillomavirus types 44 and 55 and 68a and -b. J Virol 2005;79:6565–6569.
25.
Chen Z, Terai M, Fu L, Herrero R, DeSalle R, Burk RD: Diversifying selection in human papillomavirus type 16 lineages based on complete genome analyses. J Virol 2005;79:7014–7023.
26.
Chen Z, DeSalle R, Schiffman M, Herrero R, Burk RD: Evolutionary dynamics of variant genomes of human papillomavirus types 18, 45, and 97. J Virol 2009;83:1443–1455.
27.
Ho L, Chan SY, Burk RD, Das BC, Fujinaga K, Icenogle JP, Kahn T, Kiviat N, Lancaster W, Mavromara-Nazos P, et al: The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations. J Virol 1993;67:6413–6423.
28.
Ong CK, Chan SY, Campo MS, Fujinaga K, Mavromara-Nazos P, Labropoulou V, Pfister H, Tay SK, ter Meulen J, Villa LL, et al: Evolution of human papillomavirus type 18: an ancient phylogenetic root in Africa and intratype diversity reflect coevolution with human ethnic groups. J Virol 1993;67:6424–6431.
29.
DeFilippis VR, Ayala FJ, Villarreal LP: Evidence of diversifying selection in human papillomavirus type 16 E6 but not E7 oncogenes. J Mol Evol 2002;55:491–499.
30.
Heinzel PA, Chan SY, Ho L, O’Connor M, Balaram P, Campo MS, Fujinaga K, Kiviat N, Kuypers J, Pfister H, et al: Variation of human papillomavirus type 6 (HPV-6) and HPV-11 genomes sampled throughout the world. J Clin Microbiol 1995;33:1746–1754.
31.
Chan SY, Chew SH, Egawa K, Grussendorf-Conen EI, Honda Y, Rubben A, Tan KC, Bernard HU: Phylogenetic analysis of the human papillomavirus type 2 (HPV-2), HPV-27, and HPV-57 group, which is associated with common warts. Virology 1997;239:296–302.
32.
Prado JC, Calleja-Macias IE, Bernard HU, Kalantari M, Macay SA, Allan B, Williamson AL, Chung LP, Collins RJ, Zuna RE, Dunn ST, Ortiz-Lopez R, Barrera-Saldana HA, Cubie HA, Cuschieri K, von Knebel-Doeberitz M, Sanchez GI, Bosch FX, Villa LL: Worldwide genomic diversity of the human papillomaviruses-53, 56, and 66, a group of high-risk HPVs unrelated to HPV-16 and HPV-18. Virology 2005;340:95–104.
33.
Calleja-Macias IE, Kalantari M, Huh J, Ortiz-Lopez R, Rojas-Martinez A, Gonzalez-Guerrero JF, Williamson AL, Hagmar B, Wiley DJ, Villarreal L, Bernard HU, Barrera-Saldana HA: Genomic diversity of human papillomavirus-16, 18, 31, and 35 isolates in a Mexican population and relationship to European, African, and Native American variants. Virology 2004;319:315–323.
34.
Calleja-Macias IE, Villa LL, Prado JC, Kalantari M, Allan B, Williamson AL, Chung LP, Collins RJ, Zuna RE, Dunn ST, Chu TY, Cubie HA, Cuschieri K, von Knebel-Doeberitz M, Martins CR, Sanchez GI, Bosch FX, Munoz N, Bernard HU: Worldwide genomic diversity of the high-risk human papillomavirus types 31, 35, 52, and 58, four close relatives of human papillomavirus type 16. J Virol 2005;79:13630–13640.
35.
Stewart AC, Eriksson AM, Manos MM, Munoz N, Bosch FX, Peto J, Wheeler CM: Intratype variation in 12 human papillomavirus types: a worldwide perspective. J Virol 1996;70:3127–3136.
36.
Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129–1136.
37.
Scheffner M, Huibregtse JM, Vierstra RD, Howley PM: The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993;75:495–505.
38.
Kessis TD, Slebos RJ, Nelson WG, Kastan MB, Plunkett BS, Han SM, Lorincz AT, Hedrick L, Cho KR: Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci USA 1993;90:3988–3992.
39.
Matlashewski G, Banks L, Pim D, Crawford L: Analysis of human p53 proteins and mRNA levels in normal and transformed cells. Eur J Biochem 1986;154:665–672.
40.
Veldman T, Horikawa I, Barrett JC, Schlegel R: Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J Virol 2001;75:4467–4472.
41.
Oda H, Kumar S, Howley PM: Regulation of the SRC family tyrosine kinase BLK through E6AP-mediated ubiquitination. Proc Natl Acad Sci USA 1999;96:9557–9562.
42.
Kiyono T, Hiraiwa A, Fujita M, Hayashi Y, Akiyama T, Ishibashi M: Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the drosophila discs large tumor suppressor protein. Proc Natl Acad Sci USA 1997;94:11612–11616.
43.
Dyson N, Howley PM, Munger K, Harlow E: The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934–937.
44.
Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelhutz AJ: Both rb/p16ink4a inactivation and telomerase activity are required to immortalize human epithelial cells (see comments). Nature 1998;396:84–88.
45.
Chen Z, Fu L, Herrero R, Schiffman M, Burk RD: Identification of a novel human papillomavirus (HPV97) related to HPV18 and HPV45. Int J Cancer 2007;121:2947–2952.
46.
Yasumoto S, Burkhardt AL, Doniger J, DiPaolo JA: Human papillomavirus type 16 DNA-induced malignant transformation of NIH 3T3 cells. J Virol 1986;57:572–577.
47.
Matlashewski G, Schneider J, Banks L, Jones N, Murray A, Crawford L: Human papillomavirus type 16 DNA cooperates with activated ras in transforming primary cells. EMBO J 1987;6:1741–1746.
48.
Munger K, Phelps WC, Howley PM, Schlegel R: The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989;63:4417–4421.
49.
Pim D, Collins M, Banks L: Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene 1992;7:27–32.
50.
Hiller T, Poppelreuther S, Stubenrauch F, Iftner T: Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. Cancer Epidemiol Biomarkers Prev 2006;15:1262–1267.
51.
Moscicki AB, Schiffman M, Kjaer S, Villa LL: Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine 2006;24(suppl 3):S42–S51.
52.
Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423–428.
53.
Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS: Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831–1836.
54.
Rodriguez AC, Burk R, Herrero R, Hildesheim A, Bratti C, Sherman ME, Solomon D, Guillen D, Alfaro M, Viscidi R, Morales J, Hutchinson M, Wacholder S, Schiffman M: The natural history of human papillomavirus infection and cervical intraepithelial neoplasia among young women in the Guanacaste cohort shortly after initiation of sexual life. Sex Transm Dis 2007;34:494–502.
55.
Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, Morales J, Alfaro M, Sherman ME, Wacholder S, Chen S, Rodriguez AC, Burk RD: Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005;191:1796–1807.
56.
Castle PE, Schiffman M, Gravitt PE, Kendall H, Fishman S, Dong H, Hildesheim A, Herrero R, Bratti MC, Sherman ME, Lorincz A, Schussler JE, Burk RD: Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol 2002;68:417–423.
57.
Burk RD: Human papillomavirus and the risk of cervical cancer. Hosp Pract (Off Ed) 1999;34:103–111; quiz 112.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.